Patents by Inventor Dingxie Liu

Dingxie Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
    Patent number: 11680297
    Abstract: The present inventors have identified specific oncogenic pathways preferentially activated in BRAF-mutated-melanoma cells and a pathway pattern that predicts resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors, providing novel clinical implications for melanoma therapy. In one embodiment, a method comprises (a) testing a sample oiBRAF-mutated melanoma cells isolated from a patient and measuring the expression levels of genes expressed in the following oncogenic pathways: TNFa, EGFR, IFNa, hypoxia, IFNy, STAT3 and Myc; (b) calculating a 7-pathway activation pattern based on the measured expression levels of step (a); and (c) identifying the patient's resistance level to BRAF/MEK inhibitor treatment based on comparison of the calculated 7-pathway activation pattern to a reference.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: June 20, 2023
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Michael Mingzhao Xing, Dingxie Liu
  • ACTIVITIES OF MULTIPLE CANCER-RELATED PATHWAYS ARE ASSOCIATED WITH BRAF MUTATION AND PREDICT THE RESISTANCE TO BRAF/MEK INHIBITORS IN MELANOMA CELLS
    Publication number: 20160222466
    Abstract: The present inventors have identified specific oncogenic pathways preferentially activated in BRAF-mutated-melanoma cells and a pathway pattern that predicts resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors, providing novel clinical implications for melanoma therapy. In one embodiment, a method comprises (a) testing a sample oiBRAF-mutated melanoma cells isolated from a patient and measuring the expression levels of genes expressed in the following oncogenic pathways: TNFa, EGFR, IFNa, hypoxia, IFNy, STAT3 and Myc; (b) calculating a 7-pathway activation pattern based on the measured expression levels of step (a); and (c) identifying the patient's resistance level to BRAF/MEK inhibitor treatment based on comparison of the calculated 7-pathway activation pattern to a reference.
    Type: Application
    Filed: September 16, 2014
    Publication date: August 4, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Michael Mingzhao Xing, Dingxie Liu